Biopharma deal activity in October totaled $22.31 billion, marking a 72% jump from $13.01 billion in September. Year-to-date deal values have decreased by 2%, from $175.29 billion during the first 10 months of 2023 to $171.77 billion in the same period this year, positioning 2024 as the second-highest year on record, according to BioWorld.
Gender bias in cardiac treatment guidelines is putting women at risk because guidelines are written based on clinical trials conducted mostly in men. As previously reported in BioWorld, nearly 70% of female patients are underdiagnosed for cardiovascular disease as women are grossly under-represented in clinical trials.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alvogene, Biogen, BMS, Eisai, Inflarx, Kane, Merck, Regeneron, Samsung Bioepis, Sandoz, Sanofi.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 89bio, Aurinia, Eyenovia, Janssen, Levicept, Lixa, Omega, Osteal , Pacira.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adaptimmune, Akari, Evotec, Halozyme, Kaken, Numab, Peak, TFF.
Vitalli Bio Inc. terminated a potential $477 million licensing deal for autoimmune disease drug, DWP-213388, signed a year ago with Daewoong Pharmaceutical Co. Ltd., although Vitalli still retains option rights to two more dual inhibitor candidates that could fetch up to $941 million.
RSS
